FDA Gene Therapy Draft Calls for Long-term Follow of Subjects.
The FDA recently issued multiple draft guideline documents on the fast-emerging field of gene therapy, including guidance on specific diseases like hemophilia and the need to follow some research subjects long-term to assess delayed adverse events.
| Publicado en: | IRB Advisor Vol. 18; no. 9; pp. 97 - 109 |
|---|---|
| Autor principal: | |
| Formato: | Journal Article |
| Publicado: |
Relias LLC
Sep2018
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=131308404&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 131308404 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 15352064 2SCX jtl: IRB Advisor issn: 15352064 maglogo: N pubinfo: dt: Sep2018 vid: 18 iid: 9 pid: 89126 pub: Relias LLC place: Morrisville, North Carolina artinfo: ui: 131308404 131308404 ppf: 97 ppct: 12 formats: tig: atl: FDA Gene Therapy Draft Calls for Long-term Follow of Subjects. aug: au: AHC MEDIA sug: subj: United States Food and Drug Administration Gene Therapy Adverse Effects Long Term Care Research Subjects Risk Assessment Adverse Health Care Event Patient Safety Retinal Diseases Therapy Hemophilia Therapy Rare Diseases Therapy Committees Drug Design Special Populations Consent (Research) ab: The FDA recently issued multiple draft guideline documents on the fast-emerging field of gene therapy, including guidance on specific diseases like hemophilia and the need to follow some research subjects long-term to assess delayed adverse events. pubtype: Periodical doctype: Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|